CM
REGN icon

Churchill Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Churchill Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,346
Closed -$1.46M – 131
2020
Q2 		$1.46M Buy
+2,346
New +$1.33M 0.05% 92
2019
Q2 		– Sell
-3,543
Closed -$1.46M – 121
2019
Q1 		$1.46M Buy
3,543
+1,584
+81% +$652K 0.04% 97
2018
Q4 		$732K Buy
+1,959
New +$717K 0.03% 93

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Churchill Management's REGN Position: Q3 2020 in Review

Churchill Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 2,346 shares — an estimated $1.46M sold.

Churchill Management first reported a position in REGN in Q4 2018 and held it in 3 quarters. The position peaked at $1.46M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Churchill Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Churchill Management sold 2,346 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $1.46M.
  • Churchill Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Churchill Management's Regeneron Pharmaceuticals position peaked at $1.46M in Q2 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Churchill Management's 13F filing for Q3 2020, filed 8 Oct 2020.